Reduction The Hormone Estrogen Leads To Mental Decline.
The younger a abigail is when she undergoes surgical menopause, the greater her chances of developing celebration problems at an earlier age, unexplored research suggests. Surgical menopause describes the end of ovarian perform due to gynecological surgery before the age of natural menopause. It involves the removal of one or both ovaries (an oophorectomy), often in party with a hysterectomy, the removal of a woman's uterus. "For women with surgically induced menopause, beforehand age at menopause was associated with a faster decline in memory," said den author Dr Riley Bove, an instructor in neurology at Harvard Medical School and an confederate neurologist at Brigham and Women's Hospital in Boston.
However "These are very preliminary data". Bove said other exploration suggests a link between a decrease in the hormone estrogen during menopause and mental decline, and the intent of this study was to better understand the relationship between reproductive-health factors and memory changes. The study results will be presented in March at the American Academy of Neurology' annual meeting, in San Diego.
For the study, the researchers analyzed medical records of more than 1800 women elderly 53 to 100 who were taking neighbourhood in one of two studies conducted by Rush University Medical Center in Chicago: the Religious Orders Study and the Memory and Aging Project. The researchers assessed reproductive variables, such as when women had their opening period, the numeral of years menstrual cycles lasted, and use of hormone replacement therapies. Measurements from several types of cogitative and thought tests were analyzed, too.
The scientists also assessed the results of knowledge biopsies after death, some of which showed the presence of Alzheimer's plaques. "We had approximately 580 brains elbow for analysis - this speaks to the very unique and rich nature of the data". Thirty-three percent of the reading participants had undergone surgical menopause.
Reasons for these surgeries may include fibroids (noncancerous uterine tumors), endometriosis (growth of uterine fabric outside the womb), cancer of the uterus and ovaries, and queer vaginal bleeding. When the ovaries are gone, ovarian production of estrogen stops, said Bove. However, this contemplation did not include reasons why the women underwent surgical menopause.
Showing posts with label estrogen. Show all posts
Showing posts with label estrogen. Show all posts
Tuesday 18 December 2018
Thursday 15 February 2018
Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy
Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy.
In a declaration that seems to chip the prevailing wisdom that any form of hormone replacement remedial programme raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone analysis might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone psychotherapy is actually protective" in women who have a low risk for developing mamma tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver. With his colleagues, Ragaz took another appearance at matter from the Women's Health Initiative (WHI) study, a resident trial that has focused on ways to prevent breast and colorectal cancer, as well as nature disease and fracture risk, in postmenopausal women.
The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by appearance experts, far studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.
Two groups were interest of the venture - women who had had hysterectomies and took estrogen unsurpassed as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The claque therapy trial was halted in 2002 after it became clear those women were at increased peril for heart disease and breast cancer.
In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no erstwhile history of benign knocker disease had a 43 percent reduction breast cancer risk on estrogen; women with no ancestors history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without early hormone use had a 32 percent reduced risk.
In a declaration that seems to chip the prevailing wisdom that any form of hormone replacement remedial programme raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone analysis might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone psychotherapy is actually protective" in women who have a low risk for developing mamma tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver. With his colleagues, Ragaz took another appearance at matter from the Women's Health Initiative (WHI) study, a resident trial that has focused on ways to prevent breast and colorectal cancer, as well as nature disease and fracture risk, in postmenopausal women.
The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by appearance experts, far studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.
Two groups were interest of the venture - women who had had hysterectomies and took estrogen unsurpassed as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The claque therapy trial was halted in 2002 after it became clear those women were at increased peril for heart disease and breast cancer.
In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no erstwhile history of benign knocker disease had a 43 percent reduction breast cancer risk on estrogen; women with no ancestors history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without early hormone use had a 32 percent reduced risk.
Saturday 28 January 2017
Menopause Affects Women Differently
Menopause Affects Women Differently.
Women bothered by sensual flashes or other belongings of menopause have a number of treatment options - hormonal or not, according to updated guidelines from the American College of Obstetricians and Gynecologists. It's estimated that anywhere from 50 percent to 82 percent of women thriving through menopause have simmering flashes - sudden feelings of extreme impetuosity in the upper body - and night sweats. For many, the symptoms are frequent and severe enough to cause beauty sleep problems and disrupt their daily lives.
And the duration of the misery can last from a couple years to more than a decade, says the college, the nation's unrivalled group of ob/gyns. "Menopausal symptoms are common, and can be very bothersome to women," said Dr Clarisa Gracia, who helped correspond the new guidelines. "Women should be aware that effective treatments are available to address these symptoms". The guidelines, published in the January problem of Obstetrics andamp; Gynecology, reinforce some longstanding advice: Hormone therapy, with estrogen unassisted or estrogen plus progestin, is the most effective way to cool hot flashes.
But they also offer out the growing evidence that some antidepressants can help an associate professor of obstetrics and gynecology at the University of Pennsylvania in Philadelphia. In studies, unhappy doses of antidepressants such as venlafaxine (Effexor) and fluoxetine (Prozac) have helped rescue hot flashes in some women. And two other drugs - the anti-seizure sedative gabapentin and the blood pressure medication clonidine - can be effective, according to the guidelines.
So far, though, only one non-hormonal deaden is actually approved by the US Food and Drug Administration for treating bright flashes: a low-dose version of the antidepressant paroxetine (Paxil). And experts said that while there is witness some hormone alternatives ease hot flashes, none works as well as estrogen and estrogen-progestin. "Unfortunately, many providers are nervous to prescribe hormones.
And a lot of the time, women are fearful," said Dr Patricia Sulak, an ob/gyn at Scott andamp; White Hospital in Temple, Texas, who was not knotty in letters the new guidelines. Years ago, doctors routinely prescribed hormone replacement remedy after menopause to lower women's risk of heart disease, among other things. But in 2002, a big US trial called the Women's Health Initiative found that women given estrogen-progestin pills in point of fact had slightly increased risks of blood clots, heart attack and breast cancer. "Use of hormones plummeted" after that.
Women bothered by sensual flashes or other belongings of menopause have a number of treatment options - hormonal or not, according to updated guidelines from the American College of Obstetricians and Gynecologists. It's estimated that anywhere from 50 percent to 82 percent of women thriving through menopause have simmering flashes - sudden feelings of extreme impetuosity in the upper body - and night sweats. For many, the symptoms are frequent and severe enough to cause beauty sleep problems and disrupt their daily lives.
And the duration of the misery can last from a couple years to more than a decade, says the college, the nation's unrivalled group of ob/gyns. "Menopausal symptoms are common, and can be very bothersome to women," said Dr Clarisa Gracia, who helped correspond the new guidelines. "Women should be aware that effective treatments are available to address these symptoms". The guidelines, published in the January problem of Obstetrics andamp; Gynecology, reinforce some longstanding advice: Hormone therapy, with estrogen unassisted or estrogen plus progestin, is the most effective way to cool hot flashes.
But they also offer out the growing evidence that some antidepressants can help an associate professor of obstetrics and gynecology at the University of Pennsylvania in Philadelphia. In studies, unhappy doses of antidepressants such as venlafaxine (Effexor) and fluoxetine (Prozac) have helped rescue hot flashes in some women. And two other drugs - the anti-seizure sedative gabapentin and the blood pressure medication clonidine - can be effective, according to the guidelines.
So far, though, only one non-hormonal deaden is actually approved by the US Food and Drug Administration for treating bright flashes: a low-dose version of the antidepressant paroxetine (Paxil). And experts said that while there is witness some hormone alternatives ease hot flashes, none works as well as estrogen and estrogen-progestin. "Unfortunately, many providers are nervous to prescribe hormones.
And a lot of the time, women are fearful," said Dr Patricia Sulak, an ob/gyn at Scott andamp; White Hospital in Temple, Texas, who was not knotty in letters the new guidelines. Years ago, doctors routinely prescribed hormone replacement remedy after menopause to lower women's risk of heart disease, among other things. But in 2002, a big US trial called the Women's Health Initiative found that women given estrogen-progestin pills in point of fact had slightly increased risks of blood clots, heart attack and breast cancer. "Use of hormones plummeted" after that.
Subscribe to:
Posts (Atom)